Lebreton Guillaume, Pozzi Matteo, Mastroianni Ciro, Léger Philippe, Pavie Alain, Leprince Pascal
Division of Cardiac Surgery, Pitié-Salpêtrière Hospital, University 'Pierre et Marie Curie', Paris, France
Division of Cardiac Surgery, Pitié-Salpêtrière Hospital, University 'Pierre et Marie Curie', Paris, France School in Cardiovascular Science, Cardiovascular Surgery Unit, University of Verona Medical School, Verona, Italy.
Eur J Cardiothorac Surg. 2015 Nov;48(5):785-91. doi: 10.1093/ejcts/ezu516. Epub 2015 Jan 5.
Extracorporeal life support (ECLS) devices provide temporary mechanical circulatory assistance and are usually implanted under emergency conditions in critical patients. If weaning off ECLS is not possible, heart transplantation or implantation of long-term mechanical circulatory support (LTMCS) is required. The purpose of our study was to evaluate the bridge-to-bridge (BTB) concept.
Between 1 January 2004 and 1 August 2010, 97 patients were assisted by LTMCS. The implantation was the first-line intervention in 48 patients (the bridge group), and was performed after a period of ECLS support in 49 others (the BTB group).
The long-term survival rate was 51.6%, with a mean follow-up of 30.7 months, and there were no differences for biological parameters between the two groups. Patients in the BTB group whose condition was initially more severe, improved under ECLS support, and those in whom biological parameters did not revert to normal died after LTMCS. Risk factors for mortality in the BTB group were total bilirubin and lactate before LTMCS, and alkaline phosphatase before ECLS support.
The BTB concept allows the implementation of LTMCS in severe patients, for whom it was not originally envisaged, with the same long-term survival as in first-line settings. ECLS in the evolution of patients is predictive of survival after LTMCS.
体外生命支持(ECLS)设备提供临时机械循环辅助,通常在紧急情况下植入危重症患者体内。如果无法撤离ECLS,则需要进行心脏移植或植入长期机械循环支持(LTMCS)。我们研究的目的是评估桥接至桥接(BTB)概念。
在2004年1月1日至2010年8月1日期间,97例患者接受了LTMCS辅助。48例患者(桥接组)的植入为一线干预,另外49例患者(BTB组)在接受一段时间的ECLS支持后进行了植入。
长期生存率为51.6%,平均随访30.7个月,两组生物学参数无差异。BTB组中最初病情较重的患者在ECLS支持下有所改善,而生物学参数未恢复正常的患者在LTMCS后死亡。BTB组的死亡危险因素为LTMCS前的总胆红素和乳酸,以及ECLS支持前的碱性磷酸酶。
BTB概念允许在原本未设想的重症患者中实施LTMCS,其长期生存率与一线治疗相同。患者病情进展过程中的ECLS可预测LTMCS后的生存情况。